TP53 and B-cell chronic lymphocytic leukemia: There appears to be no consistent benefit with the addition of anti-CD20 antibodies (such as rituximab and obinutuzumab) to monotherapy with BTKi in patients with TP53 disruption in the frontline management of CLL.